Advanced Enzyme Tech growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+17.1%+2.1%+15.4%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+17.8%−4.9%+30.7%
+19.7%−6.7%+39.4%
+29.6%−2.2%+31.9%
+28.7%−1.7%+26.1%
+13.4%+5.6%+8.0%
+14.6%+7.1%+6.8%
+10.0%+0.8%+0.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ADVENZYMES₹264.15

Advanced Enzyme Tech Ltd.

· Pharma & Health
₹ CrorePeersAARTIPHARMAARTIDRUGSAGARWALEYEAKUMSALIVUSAPLLTDCORONAHCGMcap ₹2,956 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+15.4+2.1+17.1—
EBITDA Growth—+30.7-4.9+17.8—
EBIT Growth—+39.4-6.7+19.7—
Net Income Growth—+31.9-2.2+29.6—
EPS Growth—+26.1-1.7+28.7—
Total Assets Growth—+8.0+5.6+13.4—
Total Equity Growth—+6.8+7.1+14.6—
Cash from Operations Growth—+0.7+0.8+10.0—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.